Currently, the most protective preerythrocytic-stage malaria vaccine candidates in human clinical trials—RTS,S and Ad-M ME.TRAP—rely on the induction of high Ab titers and powerful T-cell responses, against CS and TRAP proteins, respectively. The gene discussed is CS; the disease is malaria.